Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q3 2024 · 10-Q
Revenue$24.20M$24.20M−16.3% vs Q3 2023 Net Income-$59.60M-$59.60MN/M vs Q3 2023 EPS Diluted-$1.17-$1.17N/M vs Q3 2023 Operating Income-$62,078,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$40,875,000N/M Margins · derivedOperating margin-256.6%−31.9 pt vs Q3 2023
Net margin-246.3%−32.3 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 6, 2024 · 37 d after period end